fashion -WSS

fashion

author：hotspot 2025-10-04 11:07:33 - browse：3329

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare Advantage enrollment grows 7.1% to 33.4 million people

WSS

Abridge raises $150m as clinical notes automation market heats up

Listen: Biogen's potential pivot, & Illumina's next chapter

A rare thyroid diagnosis led to unexpected, all

Weight loss drugs aren’t covered by Obamacare. That may change

FDA warns medical device makers about rise in fabricated data

How to fix cancer clinical trials' diversity problem

explore

fashion

focus

Cancer drug shortages should be causing more outrage

What drug price negotiations mean for Medicare Part D

Alkermes shareholders re

Illumina names Agilent executive as new CEO

DIEP, the 'gold standard' of breast reconstruction, is under threat

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Supreme Court strikes down use of affirmative action

Crinetics acromegaly drug succeeds in late

After affirmative action ruling, medical educators look to 'holistic review'

NIH nominee Bertagnolli will get October confirmation hearing

Wikipedia

Medicaid rebukes states for mistakenly disenrolling children

'Make People Better': The CRISPR babies story you probably don't know

Illumina names Agilent executive as new CEO

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

The 10 drugs up first for Medicare price negotiation

Listen: Biogen's potential pivot, & Illumina's next chapter

Wikipedia

focus

leisure time

hotspot